A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

A randomized, multicenter trial, double‐blind for antiandrogen therapy, compared the antiandrogens bicalutamide and flutamide, each combined with luteinizing hormone–releasing hormone analogue therapy (LHRH‐A) in 813 patients with Stage D2 prostate carcinoma. An analysis of time to progression (median follow‐up, 95 weeks) was performed to augment previous analyses of time to treatment failure and time to death.